KEDI U.S. Dividend100 90% Participation + Daily Options Premium Index

As quarterly results typically drive price movements exceeding 10% for major energy producers, the Q2 2026 earnings release on 2026-08-06 is scheduled.

Q2 2026 earnings release is scheduled. This event is estimated to have a price impact of at least 1%.

MetLife is scheduled to release its Q2 2026 earnings results on August 5, 2026; a medium impact is expected as quarterly results are key performance indicators, scheduled.

Q3 2026 earnings release scheduled. Analysts forecast an EPS of approximately $1.63 to $1.66 forecasted. Low importance estimated: historical price reaction to earnings is typically 1-5%.

Second quarter 2026 financial results are scheduled to be released. This recurring financial event is estimated to have a medium price impact of at least 5% based on historical volatility scheduled.

Q2 2026 earnings results are scheduled to be released on 2026-07-30. A market reaction of >1% is estimated upon the actual release scheduled.

Q2 2026 earnings release is scheduled.

Q2 2026 earnings release scheduled. High importance is assigned due to the potential for significant price volatility following the earnings announcement. Analysts forecast EPS of approximately $2.79-$2.80 estimated.

The company's Q2 2026 earnings release is scheduled.

Next earnings release for Q2 2026 is expected around July 28, 2026 expected.

Q2 2026 earnings release and conference call scheduled. Market impact is estimated to be low (>=1%) as a routine announcement scheduled.

Ex-dividend date for the quarterly cash dividend of $1.02 per share on July 17, 2026, as declared on May 5, 2026. This event is estimated to have a price impact of at least 1%.

Abbott is expected to announce its Q2 2026 earnings results on July 16, 2026. This key quarterly financial update is estimated to have a moderate price impact of at least 5%, scheduled.

State Street plans to release second-quarter 2026 financial results on 2026-07-16; earnings dates for large custody banks often move shares by more than 1%, so a low-impact setup is expected scheduled.

PepsiCo is scheduled to release its second-quarter 2026 financial results on 2026-07-09, with analysts forecasting EPS of $2.22; high importance is estimated due to typical earnings-related volatility scheduled.

Next quarterly earnings report is scheduled for 2026-07-07, with analysts forecasting an EPS of $1.25; a price impact of at least 1% is forecasted.

The ex-dividend date for a quarterly dividend of $0.55 per share on July 2, 2026; dividend increase, low market impact scheduled.

President and COO Brian Evanko is scheduled to succeed David M. Cordani as Chief Executive Officer, effective July 1, 2026. This major leadership transition is estimated to have a high price impact of at least 10% due to significant changes in corporate governance scheduled.

Quarterly dividend of $0.33 per share has an ex-dividend date of July 1, 2026; a 1% price impact is expected.

NIKE, Inc. is scheduled to release its fourth quarter fiscal 2026 financial results on June 30, 2026. High importance is estimated due to the potential for significant price impact typical of major earnings releases scheduled.

The ex-dividend date for a cash dividend of $0.50 per share. The dividend is payable on July 14, 2026, to shareholders of record as of the close of business on June 30, 2026.

Darden Restaurants will report fiscal 2026 fourth quarter and full year results on June 25, 2026. Estimated price impact of ~5% based on historical earnings volatility, scheduled.

Paychex is scheduled to release its Q4 and full-year fiscal 2026 financial results on June 24, 2026; earnings releases typically cause moderate price volatility scheduled

FDA action date (PDUFA) for supplemental applications for WELIREG in combination with KEYTRUDA for the adjuvant treatment of certain patients with renal cell carcinoma (RCC) is scheduled for June 19, 2026, scheduled.

Quarterly dividend ex-date of $0.53 per share on 2026-06-15, announced on April 30, 2026, with a payment date of July 1, 2026. Low importance as dividends typically result in <5% price impact, scheduled.

Quarterly dividend of $0.85 per share has an ex-dividend date of June 15, 2026, scheduled.

Quarterly dividend of $1.30 per share, with the ex-dividend date on 2026-06-15; this distribution is estimated to cause a price impact of at least 1% scheduled.

Quarterly dividend ex-date of $0.525 per share on 2026-06-12, payable on June 29, 2026. The dividend was declared on April 28, 2026; estimated Medium impact due to yield support, scheduled.

Ex-dividend date for the regular quarterly dividend of $1.70 per share, which was declared on April 8, 2026.

Ex-dividend date for a quarterly cash dividend of $1.25 per share on 2026-06-12. The dividend was declared on May 26, 2026, and is payable on June 26, 2026. A price impact of approximately 1% is expected based on the dividend amount.

Ex-dividend date for quarterly cash dividend of $0.40 per share. The dividend was announced on April 27, 2026, and is payable on June 26, 2026, to shareholders of record on June 12, 2026, scheduled. Price impact is estimated to be low as dividends typically result in a minor price adjustment on the ex-date.

Quarterly dividend of $0.59 per share, with an ex-dividend date of June 10, 2026. The dividend is payable on June 26, 2026.

Seth Cohen, CIO of Procter & Gamble, is scheduled to speak at the 6th Annual Evercore Consumer and Retail Conference on June 10, 2026, scheduled. Low impact expected as executive conference appearances typically result in minimal price movement.

Quarterly dividend of $1.30 per share, with an ex-dividend date of June 9, 2026; Low importance as dividend announcements typically result in minor price adjustments.

Regions Financial executives are scheduled to present at the Morgan Stanley U.S. Financials Conference on June 9, 2026; low impact estimated as conference presentations typically provide incremental updates, scheduled.

Quarterly dividend ex-date on 2026-06-05, with shareholders of record to receive a cash dividend of $1.48 per share on 2026-06-30; low importance is estimated as dividend events typically have minor price impact scheduled.

Bank of America upgraded UNH to "Buy" from "Neutral" and raised its price target to $450, while Morgan Stanley raised its target to $453, citing improving medical cost trends. The stock rose over 5% on the news.

Quarterly cash dividend of $1.56 per share, with an ex-dividend date of June 4, 2026. This dividend announcement is estimated to have a low price impact of at least 1% scheduled.

Quarterly dividend of $0.92 per share (an increase from $0.89) went ex-dividend on June 4, 2026, payable on June 25, 2026. Low impact expected as the increase aligns with historical growth patterns.

Announced an investment of over $8 billion for a new Universal theme park in the United Kingdom, with construction expected to take five years; a price impact of over 10% is expected.

Presented new Phase 3 data for UPLIZNA at the EULAR 2026 Congress, showing a 0% flare rate over one year in patients with IgG4-Related Disease who continued treatment. Medium importance as positive clinical data supports market share, expected.

Artisan Partners shares fell 3% on June 3, 2026, amid a broader sell-off in asset management stocks triggered by news of a European private equity fund capping redemptions.

Announced the results of its cash tender offers for multiple series of outstanding senior notes, accepting over $4.1 billion for purchase with a settlement date of June 5, 2026; a 1% price impact is expected.

Bank OZK provided the senior mortgage in a $141 million construction financing package for the IKONIC Scottsdale in Arizona on June 3, 2026; low price impact estimated as this is a routine financing deal for the bank, expected.

Procter & Gamble's CFO stated that the company expects US market growth to return to above 3% within the next 12-18 months, expected. Low impact expected as this guidance aligns with existing market expectations.

The Board of Directors authorized a 5% increase in the quarterly cash dividend to $2.32 per share. The ex-dividend date is June 15, 2026, with payment on June 23, 2026.

Bristol Myers Squibb and partner SystImmune announced on 2026-06-02 that their ADC iza-bren showed significant Phase 3 results in TNBC and ESCC. This major clinical success is estimated to have a >10% price impact expected.

Reported a record average daily volume (ADV) for May 2026 of 33.2 million contracts on June 2, 2026, a 15% increase year-over-year; Medium importance as high trading volume often correlates with increased revenue.

KeyBanc raised its price target on MSC Industrial shares to $129 from $117 on 2026-06-02; a price impact of at least 5% is estimated due to the significant target increase.

Julie Knecht was appointed as the next Chief Financial Officer on June 2, 2026, effective August 1, 2026. Market impact is estimated to be low (>=1%) as internal successions typically maintain stability scheduled.

European Commission granted marketing authorization for IMDYLLTRA (tarlatamab) for the treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. High importance due to major drug approval potential, expected.

Announced on June 1, 2026, that the Phase 3 LITESPARK-012 study of a Keytruda-based triplet therapy in first-line advanced clear cell renal cell carcinoma (RCC) did not meet its primary endpoints.

At Computex 2026 on June 1, 2026, Qualcomm unveiled its 'Dragonfly' brand for data center AI inference chips, signaling a major push into the AI data center market. Medium impact expected due to strategic entry into a high-growth segment.

Appointment of Ryan P. Nolan to the Board of Directors, effective June 1, 2026.

The U.S. FDA accepted for Priority Review the sNDA for Camzyos on 2026-06-01. This regulatory milestone is estimated to have a >1% price impact expected.

Announced on 2026-06-01 it is exploring a potential public listing in India for its largest bottling unit, Hindustan Coca-Cola Holdings, for 2027. Low importance as the listing is a long-term exploration with no immediate financial impact, scheduled.

The ex-dividend date for a quarterly cash dividend of $0.265 per common share occurred on June 1, 2026; the dividend was declared on April 15, 2026.

Announced positive Phase 3 SUCCESSOR-2 trial results on 2026-05-29 showing a 52% reduction in disease progression risk for multiple myeloma. This breakthrough is estimated to have a >10% price impact expected.

Launched 24/7 trading for Cryptocurrency futures and options, effective May 29, 2026, to provide continuous market access; Medium importance due to the strategic expansion into 24/7 crypto markets.

Received FDA Breakthrough Therapy designation for calderasib (MK-1084) on May 29, 2026. Medium importance as this designation accelerates the development of a key oncology candidate.